Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease

Applied Microbiology and Biotechnology

Volumn 99, Issue 20, 2015, Pages 8549-8562

  Kandalaft, Hiba ^a   Hussack, Greg ^a   Aubry, Annie ^a   van Faassen, Henk ^a   Guan, Yonghong ^a   Arbabi Ghahroudi, Mehdi ^a,b,c   MacKenzie, Roger ^a,c   Logan, Susan M ^a,d   Tanha, Jamshid ^a,c,d  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Clostridium difficile; Nanobody; Single domain antibody; Surface layer protein; VHH

Indexed keywords

CLOSTRIDIUM; EPITOPES; MOLECULAR WEIGHT; PROTEINS;

BINDING SPECIFICITIES; CLOSTRIDIUM DIFFICILE; GASTROINTESTINAL INFECTIONS; HIGH MOLECULAR WEIGHT; NANOBODY; PHAGE DISPLAY LIBRARIES; SINGLE-DOMAIN ANTIBODIES; SURFACE LAYERS;

ANTIBODIES;

EPITOPE; MEMBRANE PROTEIN; NANOBODY; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; PEPTIDE LIBRARY; PROTEIN BINDING; S-LAYER PROTEINS;

ANTIBIOTIC RESISTANCE; ANTIBODY; BACTERIUM; BIOTECHNOLOGY; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; GASTROENTERITIS; IMMUNIZATION; PROTEIN; TOXIN;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BACTERIAL CELL; BINDING AFFINITY; CLOSTRIDIUM INFECTION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; NONHUMAN; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ISOLATION AND PURIFICATION; LOCOMOTION; METABOLISM; PEPTIDE LIBRARY; PHYSIOLOGY;

NORTH AMERICA;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; CRICETINAE; LAMA (MAMMAL);

ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; EPITOPES; LOCOMOTION; MEMBRANE GLYCOPROTEINS; PEPTIDE LIBRARY; PROTEIN BINDING; SINGLE-DOMAIN ANTIBODIES;

EID: 84941992759     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-015-6594-1     Document Type: Article

References (82)

1. Adams H, Horrevoets WM, Adema SM, Carr HE, van Woerden RE, Koster M, Tommassen J (2014) Inhibition of biofilm formation by camelid single-domain antibodies against the flagellum of Pseudomonas aeruginosa. J Biotechnol 186:66–73
2. Adawi A, Bisignano C, Genovese T, Filocamo A, Khouri-Assi C, Neville A, Feuerstein GZ, Cuzzocrea S, Neville LF (2012) In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa. Int J Mol Med 30:455–464
3. Åkerlund T, Persson I, Unemo M, Norén T, Svenungsson B, Wullt M, Burman LG (2008) Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol 46:1530–1533
4. Ausiello CM, Cerquetti M, Fedele G, Spensieri F, Palazzo R, Nasso M, Frezza S, Mastrantonio P (2006) Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect 8:2640–2646
5. Bianco M, Fedele G, Quattrini A, Spigaglia P, Barbanti F, Mastrantonio P, Ausiello CM (2011) Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. J Med Microbiol 60:1162–1167
6. Bourgault AM, Lamothe F, Loo VG, Poirier L (2006) In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother 50:3473–3475
7. Calabi E, Fairweather N (2002) Patterns of sequence conservation in the S-layer proteins and related sequences in Clostridium difficile. J Bacteriol 184:3886–3897
8. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, Dell A, Dougan G, Fairweather N (2001) Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 40:1187–1199
9. Calabi E, Calabi F, Phillips AD, Fairweather NF (2002) Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infec Immun 70:5770–5778
10. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6:17–27
11. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN (2009) Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 15:230–233
12. Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3:541–548
13. Collins LE, Lynch M, Marszalowska I, Kristek M, Rochfort K, O’Connell M, Windle H, Kelleher D, Loscher CE (2014) Surface layer proteins isolated from Clostridium difficile induce clearance responses in macrophages. Microbes Infect 16:391–400
14. Drudy D, O’Donoghue DP, Baird A, Fenelon L, O’Farrelly C (2001) Flow cytometric analysis of Clostridium difficile adherence to human intestinal epithelial cells. J Med Microbiol 50:526–534
15. Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly CP (2004) Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 41:237–242
16. Dubberke ER, Olsen MA (2012) Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl 2):S88–S92
17. Dubreuil JD, Logan SM, Cubbage S, Eidhin DN, McCubbin WD, Kay CM, Beveridge TJ, Ferris FG, Trust TJ (1988) Structural and biochemical analyses of a surface array protein of Campylobacter fetus. J Bacteriol 170:4165–4173
18. Dupuy B, Govind R, Antunes A, Matamouros S (2008) Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 57:685–689
19. Fagan RP, Fairweather NF (2014) Biogenesis and functions of bacterial S-layers. Nat Rev Microbiol 12:211–222
20. Fagan RP, Albesa-Jove D, Qazi O, Svergun DI, Brown KA, Fairweather NF (2009) Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol 71:1308–1322
21. Forbes SJ, Eschmann M, Mantis NJ (2008) Inhibition of Salmonella enterica serovar Typhimurium motility and entry into epithelial cells by a protective antilipopolysaccharide monoclonal immunoglobulin A antibody. Infect Immun 76:4137–4144
22. Forgetta V, Oughton MT, Marquis P, Brukner I, Blanchette R, Haub K, Magrini V, Mardis ER, Gerding DN, Loo VG, Miller MA, Mulvey MR, Rupnik M, Dascal A, Dewar K (2011) Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficile. J Clin Microbiol 49:2230–2238
23. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74:309–318
24. Ghose C (2013) Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect 2:e62
25. Giannasca PJ, Warny M (2004) Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848–856
26. Gilca R, Hubert B, Fortin E, Gaulin C, Dionne M (2010) Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Québec, Canada, 1998-2006. Infect Control Hosp Epidemiol 31:939–947
27. Govaert J, Pellis M, Deschacht N, Vincke C, Conrath K, Muyldermans S, Saerens D (2012) Dual beneficial effect of interloop disulfide bond for single domain antibody fragments. J Biol Chem 287:1970–1979
28. Grogono-Thomas R, Dworkin J, Blaser MJ, Newell DG (2000) Roles of the surface layer proteins of Campylobacter fetus subsp. fetus in ovine abortion. Infect Immun 68:1687–1691
29. Hamadeh RM, Estabrook MM, Zhou P, Jarvis GA, Griffiss JM (1995) Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing. Infect Immun 63:4900–4906
30. Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77:13–22
31. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B (2000) Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 37:579–590
32. Harmsen MM, van Solt CB, Fijten HP, van Keulen L, Rosalia RA, Weerdmeester K, Cornelissen AH, De Bruin MG, Eble PL, Dekker A (2007) Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 120:193–206
33. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136
34. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484–490
35. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, Dionne M, Lorange M (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 44:238–244
36. Hunt JJ, Ballard JD (2013) Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev 77:567–581
37. Hussack G, Tanha J (2010) Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins 2:998–1018
38. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R, Tanha J (2011a) Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286:8961–8976
39. Hussack G, Hirama T, Ding W, Mackenzie R, Tanha J (2011b) Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS One 6:e28218
40. Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J (2012) Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies. Methods Mol Biol 911:211–239
41. Hussack G, Riazi A, Ryan S, van Faassen H, MacKenzie R, Tanha J, Arbabi-Ghahroudi M (2014) Protease-resistant single-domain antibodies inhibit Campylobacter jejuni motility. Protein Eng Des Sel 27:191–198
42. Jank T, Aktories K (2008) Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16:222–229
43. Jank T, Giesemann T, Aktories K (2007) Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17:15R–22R
44. Janvilisri T, Scaria J, Thompson AD, Nicholson A, Limbago BM, Arroyo LG, Songer JG, Gröhn YT, Chang YF (2009) Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol 191:3881–3891
45. Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1–8
46. H domains. Methods Mol Biol 911:355–372
47. H domains. Protein Eng Des Sel 25:581–589
48. Kim DY, Hussack G, Kandalaft H, Tanha J (2014) Mutational approaches to improve the biophysical properties of human single-domain antibodies. Biochim Biophys Acta 1844:1983–2001
49. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449
50. Lynch SV, Wiener-Kronish JP (2008) Novel strategies to combat bacterial virulence. Curr Opin Crit Care 14:593–599
51. MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, Henwick S (2006) Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44:2147–2152
52. Mauri PL, Pietta PG, Maggioni A, Cerquetti M, Sebastianelli A, Mastrantonio P (1999) Characterization of surface layer proteins from Clostridium difficile by liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 13:695–703
53. Merrigan MM, Venugopal A, Roxas JL, Anwar F, Mallozzi MJ, Roxas BA, Gerding DN, Viswanathan VK, Vedantam G (2013) Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One 8:e78404
54. Monot M, Boursaux-Eude C, Thibonnier M, Vallenet D, Moszer I, Medigue C, Martin-Verstraete I, Dupuy B (2011) Reannotation of the genome sequence of Clostridium difficile strain 630. J Med Microbiol 60:1193–1199
55. Ni Eidhin DB, O’Brien JB, McCabe MS, Athie-Morales V, Kelleher DP (2008) Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 52:207–218
56. O’Brien JB, McCabe MS, Athie-Morales V, McDonald GS, Ni Eidhin DB, Kelleher DP (2005) Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett 246:199–205
57. Pantosti A, Cerquetti M, Viti F, Ortisi G, Mastrantonio P (1989) Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea. J Clin Microbiol 27:2594–2597
58. Péchiné S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, Collignon A (2007) Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25:3946–3954
59. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D (2004) Clostridium difficile-associated diarrhea in a region of Québec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472
60. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Québec. Clin Infect Dis 41:1254–1260
61. Riazi A, Strong PC, Coleman R, Chen W, Hirama T, van Faassen H, Henry M, Logan SM, Szymanski CM, Mackenzie R, Ghahroudi MA (2013) Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens. PLoS One 8:e83928
62. Ryan A, Lynch M, Smith SM, Amu S, Nel HJ, McCoy CE, Dowling JK, Draper E, O’Reilly V, McCarthy C, O’Brien J, Ni Eidhin D, O’Connell MJ, Keogh B, Morton CO, Rogers TR, Fallon PG, O’Neill LA, Kelleher D, Loscher CE (2011) A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog 7:e1002076
63. Saerens D, Conrath K, Govaert J, Muyldermans S (2008) Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol 377:478–488
64. Sara M, Sleytr UB (2000) S-Layer proteins. J Bacteriol 182:859–868
65. Schmidt C, Löffler B, Ackermann G (2007) Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn Microbiol Infect Dis 59:1–5
66. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, Holden MT, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38:779–786
67. Sleytr UB, Beveridge TJ (1999) Bacterial S-layers. Trends Microbiol 7:253–260
68. Spigaglia P, Barbanti F, Mastrantonio P (2008) Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile. Antimicrob Agents Chemother 52:770–773
69. Spigaglia P, Galeotti CL, Barbanti F, Scarselli M, Van Broeck J, Mastrantonio P (2011) The LMW surface-layer proteins of Clostridium difficile PCR ribotypes 027 and 001 share common immunogenic properties. J Med Microbiol 60:1168–1173
70. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102
71. Takumi K, Susami Y, Takeoka A, Oka T, Koga T (1991) S layer protein of Clostridium tetani: purification and properties. Microbiol Immunol 35:569–575
72. HH properties. J Immunol Methods 263:97–109
73. Hs by a phage selection. J Biol Chem 280:41395–41403
74. Twine SM, Reid CW, Aubry A, McMullin DR, Fulton KM, Austin J, Logan SM (2009) Motility and flagellar glycosylation in Clostridium difficile. J Bacteriol 191:7050–7062
75. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, Hammarstrom L, van Klinken BJ (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24:4130–4137
76. Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E, De Greve H, Depicker A (2013) Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenic Escherichia coli infection. Proc Natl Acad Sci U S A 110:11809–11814
77. Warny M, Pépin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084
78. Waseh S, Hanifi-Moghaddam P, Coleman R, Masotti M, Ryan S, Foss M, MacKenzie R, Henry M, Szymanski CM, Tanha J (2010) Orally administered P22 phage tailspike protein reduces Salmonella colonization in chickens: prospects of a novel therapy against bacterial infections. PLoS One 5:e13904
79. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198:157–174
80. Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H (2014) A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 210:964–972
81. HH by mutational hotspot randomization. J Immunol Methods 297:213–224
82. Zabetakis D, Olson MA, Anderson GP, Legler PM, Goldman ER (2014) Evaluation of disulfide bond position to enhance the thermal stability of a highly stable single domain antibody. PLoS One 9:e115405